STOCK TITAN

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Adaptive Biotechnologies Corporation (ADPT) will be participating in the TD Cowen 44th Annual Healthcare Conference in Boston, MA. The management will present on March 4th, providing a live and archived webcast for interested parties.
Positive
  • None.
Negative
  • None.

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming TD Cowen 44th Annual Healthcare Conference in Boston, MA.

Adaptive Biotechnologies’ management is scheduled to present on Monday, March 4th at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com


FAQ

When will Adaptive Biotechnologies Corporation present at the TD Cowen 44th Annual Healthcare Conference?

Adaptive Biotechnologies Corporation will present on Monday, March 4th at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern Time.

Where can interested parties access the live and archived webcast of the presentation?

Interested parties can access the live and archived webcast of the presentation on the 'Investors' section of the company website at www.adaptivebiotech.com.

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

ADPT Rankings

ADPT Latest News

ADPT Stock Data

411.16M
96.82M
2.83%
97.6%
6.27%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SEATTLE

About ADPT

we are a commercial-stage, biotechnology organization located in the hot biotech locations of seattle, washington and south san francisco, ca. our world class scientists have invented a patent-pending technology that combines advances in high-throughput sequencing with state-of-the-art computer infrastructure to provide an in-depth analysis of the t- and b-cell repertoire, a specific and important part of the immune system. this information is driving the r&d community to support the fights against cancer, auto-immune disease, and much, much more. we're often asked to describe our company culture. it is very easy ... we're a hard working group of top-notch individuals who are passionate about wanting to make a difference in the world. we know our employees are our most valuable asset, and every employee’s contribution is appreciated. open communication and collaboration are always encouraged in every interaction throughout the organization. we have high expectations of ourselves, and